Comparison of Short-term Sustained-release Opioid in Open Abdominal Urologic Surgeries
- Registration Number
- NCT05375916
- Lead Sponsor
- University of Alberta
- Brief Summary
The advantage of slow-release opioid allows for less fluctuation in drug (pain killer) levels in the blood and an extended period within the effective range for pain relief. The slow-release opioids have been preferred over the short-acting opioids because of the longer duration of action, which lessens the frequency and severity of end-of-dose pain.
Herein, the investigators propose the use of low dose slow-release opioid formulation offers better pain control in the first 48 hours post-operatively in open abdominal urologic surgeries.
- Detailed Description
This will be a randomized, double-blind, controlled trial looking at all adult patients undergoing open abdominal urologic surgeries. After assessing the inclusion/exclusion criteria, the patients will be randomized into one of two groups:
Group 1: Sustained-release (long-acting) opioid on a regular basis for 2 days with immediate-release (short-acting) opioid available on an 'as required' basis
Group 2: Immediate-release (short-acting) opioid on an 'as required' basis only.
All patients will have a general anesthetic at the discretion of the anesthesiologist in the operating room and intravenous opioid will be administered in accordance with the anesthesiologists' discretion.
Pain score and analgesic consumption are the outcome measures.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 80
- All adult patients undergoing open abdominal urologic surgeries
- ASA 1-3
- Patient refusal
- history of chronic pain
- allergy to hydromorphone
- cannot swallow tablets
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Sustained-release opioid Hydromorphone 3mg of sustained-release hydromorphone three times a day Short-acting opioid Hydromorphone 1-4 mg of short-acting hydromorphone 2-4 times a day as needed
- Primary Outcome Measures
Name Time Method Time to Mobilization Time to mobilize postoperatively up to 5 days Ability to walk from bed to chair
- Secondary Outcome Measures
Name Time Method Pain score postoperatively day 1, 2, 3 Pain score using visual analogue scale 0-100
Opioid consumption of hydromorphone Postoperatively in recovery, 24 hours, 48 hours and 72 hours postoperatively Consumption of hydromorphone
Trial Locations
- Locations (1)
University of Alberta Hospital
🇨🇦Edmonton, Alberta, Canada